Table 3.
Treatment compliance according to PNI
| Characteristics | PNI before chemotherapy
|
||
|---|---|---|---|
| <50 | ≥50 | P-value | |
| PB chemotherapy | |||
| Patients, number | 29 | 24 | |
| Treatment compliance | 0.999 | ||
| 4 cycle (complete) | 27 (93.1%) | 23 (95.8%) | |
| ≤3 cycle | 2 | 1 | |
| Treatment discontinuation reason | |||
| Adverse effect | 2 | 0 | |
| Recurrence | 0 | 1 | |
| Oral-FT chemotherapy | |||
| Patients, number | 25 | 28 | |
| Treatment compliance | 0.010 | ||
| Completea | 9 (36.0%) | 20 (71.4%) | |
| Incomplete | 16 | 8 | |
| Treatment discontinuation reason | |||
| Adverse effect | 8 | 4 | |
| Recurrence | 8 | 4 | |
Notes:
a
Complete; UFT: 2 years, S-1: 1 year.
Abbreviations: PNI, prognostic nutritional index; UFT, tegafur–uracil; PB, platinum-based; FT, tegafur.